Research Library / Metabolic / Eloralintide
Metabolic researchEloralintide (Elora)
Elora · LY3841136 · Long-acting amylin receptor agonist
An investigational once-weekly peptide designed to engage amylin-mediated appetite and metabolic signaling without incretin receptor agonism. The trial-derived reference (Phase 2 fixed-dose reference) lists 1, 3, 6, or 9 mg per administration, once weekly, via subcutaneous; it is not a universal community schedule. An illustrative 10 mg vial at an assumed 1 mL final volume yields 10 mg/mL; diluent compatibility remains product-specific. For research and education only, not personal medical guidance.
Quick Reference
- Example vial
- 10mg
- Assumed final volume
- 1mL · not an amount to add
- Concentration
- 10mg/mL · conditional arithmetic
- One U-100 marking
- 100mcg in 0.01 mL
Hypothetical vial math does not reproduce a study formulation or verify a diluent, sterility or storage period.
Research schedules
| Context / phase | Amount | Schedule total | Frequency | Timing | Route | Evidence |
|---|---|---|---|---|---|---|
| Phase 2 fixed-dose reference | 1, 3, 6, or 9 mg | 1–9 mg/week | Once weekly | Same day each week | Subcutaneous | Trial-derived reference |
| Phase 2 escalation reference | 3 → 6 → 9 mg | Escalated weekly dose | Once weekly | Same day each week | Subcutaneous | Trial-derived reference |
Once-weekly eloralintide versus placebo; phase 3 dose-arm details are not inferred from phase 2. Participation approximately 75 weeks without prediabetes or 196 weeks with prediabetes, including study visits and follow-up; not a community cycle.
Planned 1,980 adults with obesity or overweight, without type 2 diabetesSponsor trial record · NCT07321886; reviewed November 1, 20261, 3, 6 or 9 mg; or escalation to 9 mg from 6 or 3 mg · subcutaneous · once weekly · 48 weeks
263 adults with obesity, or overweight with a weight-related comorbidity, without type 2 diabetesLancet, 2025No separate schedule of this evidence type is recorded. The cited research and formulation notes remain available below.
Repeated community reports do not establish identity, safety, effectiveness or an appropriate exposure. Component schedules do not validate a same-vial blend.
Vial calculator
Linked to Quick Reference and compatible supply calculations.
Read the needle-side edge of the black stopper. Liquid tint is illustrative.
Scale illustration · one U-100 marking = 0.01 mL.
Arithmetic yield at this example amount
10 example portions per vial
10 full amounts; 0 mg remaining. Yield is not a storage or reuse period.
See the calculation
Concentration = vial content ÷ final volume. Volume = example amount ÷ concentration. U-100 markings = mL × 100.
Original example & formulation context
1 mg trial-dose math · 10 mg/mL · 0.1 mL · 10 units
Arithmetic for a hypothetical 10 mg research vial only: 3 mg equals 0.30 mL (30 units), 6 mg equals 0.60 mL (60 units), and 9 mg equals 0.90 mL (90 units). This does not reproduce Lilly's sponsor-controlled trial formulation. A published preclinical comparison formulated eloralintide in pH-8 buffer and cagrilintide in pH-4 buffer. This observation belongs to that experiment, not a human trial-vial mixing instruction. The calculation assumes the stated final solution volume, which may differ from liquid added. It does not verify dissolution, solvent compatibility, sterility, chemical stability or storage. See the source-linked preparation notes below.
Supplies & vial yield
Supply total not calculated
10 mg (hypothetical) · 1 mL assumed final solution volume; diluent product-specific
No single, consistently reported subcutaneous amount-and-frequency pair is available for a responsible automatic supply calculation.
*Conditional mass and final-volume arithmetic. No stability, sterility, safe reuse period or verified diluent quantity is established. Cleansing materials, sterile supplies, labels and sharps disposal follow the actual research procedure.
Protocol overview & research context
- Identity
- Eloralintide · Elora · LY3841136 · Long-acting amylin receptor agonist
- Evidence / status
- Phase III. Investigational — not FDA approved
- Clinical route, frequency & duration
ENLIGHTEN-1 phase 3 development: Once-weekly eloralintide versus placebo; phase 3 dose-arm details are not inferred from phase 2. Participation approximately 75 weeks without prediabetes or 196 weeks with prediabetes, including study visits and follow-up; not a community cycle.
Phase 2 obesity trial: 1, 3, 6 or 9 mg; or escalation to 9 mg from 6 or 3 mg · subcutaneous · once weekly · 48 weeks
- Community purpose
- Appetite suppression, satiety, and weight-management research.
Loading, titration and maintenance
A separate loading phase is not identified in this library entry. Titration, maintenance and stopping rules depend on the specific product or study; a listed range is not automatically an escalation plan.
Reconstitution & formulation
A published preclinical comparison formulated eloralintide in pH-8 buffer and cagrilintide in pH-4 buffer. This observation belongs to that experiment, not a human trial-vial mixing instruction.
Other vehicles and approaches discussed
Community BAC-water/acid questions remain unresolved. Cagrilintide acid advice must not be transferred automatically to eloralintide.
- Evidence context
- Product / laboratory / report distinctions apply
- Cloudiness / gel signal
- Compound-specific buffer requirements unresolved
- Product details to verify
- Verify the exact product, sequence/salt form, buffer and excipients, concentration, route, container and product-specific storage instructions.
Sources apply to the named product, laboratory method or report only. Laboratory solvents and community repetition do not establish an injectable preparation, sterility, chemical stability or a beyond-use period. No solvent-mixing or salvage recipe is provided.
Preparation references reviewed October 20, 2026.
Preparation documentation checklist
- Confirm identity, nominal content, salt form, buffer and excipients.
- Verify the actual product's diluent, amount to add and intended method.
- Calculate concentration from final solution volume, and cross-check units.
- Record lot, concentration, diluent, preparation date, storage and discard instructions.
This checklist does not replace a validated preparation procedure.
Storage, clarity & stability
- Unopened product
- Follow its documented temperature, light protection, shipping and expiration requirements.
- Prepared material
- Chemical stability and microbial safety are formulation-specific. A diluent bottle's discard period does not establish the compound's storage period.
- Visible-change context
- Compound-specific buffer requirements unresolved
Unexpected cloudiness, particles or gel
For a product intended to form a clear solution, do not use or attempt to salvage unexpected persistent clouding, strings, precipitate, thickening or gel. Labeled suspensions, including some triptorelin depots, have their own expected appearance and instructions.
Why vial yield does not establish shelf life
Arithmetic portions assume the material remains usable. Chemical degradation, contamination, handling losses and required discard limits may reduce practical yield. Freezing, warming, acidifying or further diluting cannot be assumed to restore quality.
No universal refrigerated, room-temperature or 90-day beyond-use period is assigned by the calculator.
How it works
Selective amylin receptor agonist
An investigational once-weekly peptide designed to engage amylin-mediated appetite and metabolic signaling without incretin receptor agonism.
Community-reported purpose
Appetite suppression, satiety, and weight-management research.
Reported purposes and marketing use-cases are not an approved indication or proof of efficacy.
Clinical findings & study landscape
ENLIGHTEN-1 phase 3 development
Protocol: Once-weekly eloralintide versus placebo; phase 3 dose-arm details are not inferred from phase 2. Participation approximately 75 weeks without prediabetes or 196 weeks with prediabetes, including study visits and follow-up; not a community cycle.
Population: Planned 1,980 adults with obesity or overweight, without type 2 diabetes
Read the cited evidencePhase 2 obesity trial
Protocol: 1, 3, 6 or 9 mg; or escalation to 9 mg from 6 or 3 mg · subcutaneous · once weekly · 48 weeks
Population: 263 adults with obesity, or overweight with a weight-related comorbidity, without type 2 diabetes
Read the cited evidenceFindings apply to the tested product, population and methods. A registry listing, mechanistic study or evidence-landscape link is not itself proof of efficacy or validation of an online vial.
Safety, evidence limits & regulatory status
Compound-specific safety context
Nausea and fatigue were the most common adverse events and varied by dose and escalation arm. The trial does not establish an approved treatment or self-use protocol.
Development and regulatory status
Investigational — not FDA approved
Approval of a named product does not extend to every vial, formulation, route, blend or indication carrying a related name.
What this guide cannot establish
The library does not authenticate a product or determine a personal starting dose, missed-dose rule, restart regimen, interaction plan or combination protocol. Study schedules, community reports and vial calculations retain separate evidence labels.
Frequently asked questions
What is Eloralintide?
An investigational once-weekly peptide designed to engage amylin-mediated appetite and metabolic signaling without incretin receptor agonism.
Selective amylin receptor agonist
Does vial strength mean the amount per administration?
No. A vial's label states nominal contents. The amount used in a study belongs to its assigned product and protocol. Changing vial strength changes concentration and yield, not the study's assigned amount.
Why does changing final volume change the U-100 value?
A larger final volume reduces concentration for the same mass. U-100 markings are volume measurements: one marking equals 0.01 mL. They are not biological international units of a peptide.
What happens when a calculation exceeds one syringe or vial?
Available mass and syringe capacity are separate limits. The calculator flags a result above 1 mL; it does not provide a splitting or combining technique.
Is there a loading phase or standard cycle?
A separate loading phase is not identified in this entry. Do not infer one from a range of reported amounts.
Cycle length is not established as a universal protocol.
Which diluent and storage period should this material use?
A published preclinical comparison formulated eloralintide in pH-8 buffer and cagrilintide in pH-4 buffer. This observation belongs to that experiment, not a human trial-vial mixing instruction.
Calculation examples do not establish solvent compatibility, sterility or shelf life.
Where do I track or calculate a multi-phase schedule?
The Free Planner supports saved research examples and multi-phase planning. This guide's calculator is local to the page and does not save a protocol automatically.
Open Free PlannerReferences & evidence trail
- Clinical / regulatory / evidence landscapeSponsor trial record · NCT07321886; reviewed November 1, 2026: ENLIGHTEN-1 phase 3 development
- Clinical / regulatory / evidence landscapeLancet, 2025: Phase 2 obesity trial
- Research study — applies to its stated conditionsEloralintide discovery/translational study
- Community/vendor report — unvalidatedEloralintide BAC/acid discussion
Clinical sources remain attached to their studies; laboratory and community formulation sources retain their own limits. Preparation review dates do not imply that every clinical study was newly reviewed today.
Independent educational research reference. Not medical advice or an individualized dosing recommendation.